Logo image of RVMD

REVOLUTION MEDICINES INC (RVMD) Stock Fundamental Analysis

NASDAQ:RVMD - US76155X1000 - Common Stock

38.85 USD
-0.92 (-2.31%)
Last: 9/4/2025, 2:41:58 PM
Fundamental Rating

3

RVMD gets a fundamental rating of 3 out of 10. The analysis compared the fundamentals against 542 industry peers in the Biotechnology industry. RVMD has a great financial health rating, but its profitability evaluates not so good. RVMD does not seem to be growing, but still is valued expensively.


Dividend Valuation Growth Profitability Health

Quickly go to:

1

1. Profitability

1.1 Basic Checks

RVMD had negative earnings in the past year.
RVMD had a negative operating cash flow in the past year.
In the past 5 years RVMD always reported negative net income.
In the past 5 years RVMD always reported negative operating cash flow.
RVMD Yearly Net Income VS EBIT VS OCF VS FCFRVMD Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2017 2018 2019 2020 2021 2022 2023 2024 0 -200M -400M -600M

1.2 Ratios

The Return On Assets of RVMD (-23.46%) is better than 74.17% of its industry peers.
With an excellent Return On Equity value of -26.49%, RVMD belongs to the best of the industry, outperforming 80.07% of the companies in the same industry.
Industry RankSector Rank
ROA -23.46%
ROE -26.49%
ROIC N/A
ROA(3y)-25.08%
ROA(5y)-24.01%
ROE(3y)-28.89%
ROE(5y)-28.2%
ROIC(3y)N/A
ROIC(5y)N/A
RVMD Yearly ROA, ROE, ROICRVMD Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2017 2018 2019 2020 2021 2022 2023 2024 -200 -400 -600

1.3 Margins

RVMD does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
RVMD Yearly Profit, Operating, Gross MarginsRVMD Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2017 2018 2019 2020 2021 2022 2023 2024 -1K -2K -3K -4K

More info and screens

8

2. Health

2.1 Basic Checks

RVMD does not have a ROIC to compare to the WACC, probably because it is not profitable.
The number of shares outstanding for RVMD has been increased compared to 1 year ago.
Compared to 5 years ago, RVMD has more shares outstanding
RVMD has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
RVMD Yearly Shares OutstandingRVMD Yearly Shares OutstandingYearly Shares Outstanding 2017 2018 2019 2020 2021 2022 2023 2024 50M 100M 150M
RVMD Yearly Total Debt VS Total AssetsRVMD Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2017 2018 2019 2020 2021 2022 2023 2024 500M 1B 1.5B 2B 2.5B

2.2 Solvency

RVMD has an Altman-Z score of 14.39. This indicates that RVMD is financially healthy and has little risk of bankruptcy at the moment.
The Altman-Z score of RVMD (14.39) is better than 88.93% of its industry peers.
There is no outstanding debt for RVMD. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z 14.39
ROIC/WACCN/A
WACC9.86%
RVMD Yearly LT Debt VS Equity VS FCFRVMD Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2017 2018 2019 2020 2021 2022 2023 2024 0 500M -500M 1B 1.5B 2B

2.3 Liquidity

RVMD has a Current Ratio of 14.20. This indicates that RVMD is financially healthy and has no problem in meeting its short term obligations.
With an excellent Current ratio value of 14.20, RVMD belongs to the best of the industry, outperforming 88.75% of the companies in the same industry.
A Quick Ratio of 14.20 indicates that RVMD has no problem at all paying its short term obligations.
The Quick ratio of RVMD (14.20) is better than 88.93% of its industry peers.
Industry RankSector Rank
Current Ratio 14.2
Quick Ratio 14.2
RVMD Yearly Current Assets VS Current LiabilitesRVMD Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2017 2018 2019 2020 2021 2022 2023 2024 500M 1B 1.5B 2B

More info and screens

3

3. Growth

3.1 Past

The earnings per share for RVMD have decreased strongly by -23.52% in the last year.
RVMD shows a very negative growth in Revenue. In the last year, the Revenue has decreased by -100.00%.
EPS 1Y (TTM)-23.52%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-61.73%
Revenue 1Y (TTM)-100%
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A

3.2 Future

RVMD is expected to show quite a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 19.04% yearly.
Based on estimates for the next years, RVMD will show a very strong growth in Revenue. The Revenue will grow by 442.36% on average per year.
EPS Next Y-49.65%
EPS Next 2Y-28.29%
EPS Next 3Y-18.15%
EPS Next 5Y19.04%
Revenue Next Year2012.42%
Revenue Next 2Y914.86%
Revenue Next 3Y697.5%
Revenue Next 5Y442.36%

3.3 Evolution

RVMD Yearly Revenue VS EstimatesRVMD Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 1B 2B 3B
RVMD Yearly EPS VS EstimatesRVMD Yearly EPS VS EstimatesYearly EPS VS Estimates 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 0 5 -5 10 15 20

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for RVMD. In the last year negative earnings were reported.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for RVMD. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
RVMD Price Earnings VS Forward Price EarningsRVMD Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
RVMD Per share dataRVMD EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 5 -5 10

4.3 Compensation for Growth

A cheap valuation may be justified as RVMD's earnings are expected to decrease with -18.15% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-28.29%
EPS Next 3Y-18.15%

More info and screens

0

5. Dividend

5.1 Amount

RVMD does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

REVOLUTION MEDICINES INC

NASDAQ:RVMD (9/4/2025, 2:41:58 PM)

38.85

-0.92 (-2.31%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)08-06 2025-08-06/amc
Earnings (Next)11-04 2025-11-04/amc
Inst Owners104.9%
Inst Owner Change-3.47%
Ins Owners2.01%
Ins Owner Change2.69%
Market Cap7.26B
Analysts87.37
Price Target73.83 (90.04%)
Short Float %8.33%
Short Ratio6.32
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)0
Avg EPS beat(2)-7.21%
Min EPS beat(2)-11.25%
Max EPS beat(2)-3.17%
EPS beat(4)1
Avg EPS beat(4)-2.22%
Min EPS beat(4)-11.25%
Max EPS beat(4)8.02%
EPS beat(8)3
Avg EPS beat(8)-3.58%
EPS beat(12)6
Avg EPS beat(12)0.14%
EPS beat(16)7
Avg EPS beat(16)-1.53%
Revenue beat(2)0
Avg Revenue beat(2)-100%
Min Revenue beat(2)-100%
Max Revenue beat(2)-100%
Revenue beat(4)0
Avg Revenue beat(4)-100%
Min Revenue beat(4)-100%
Max Revenue beat(4)-100%
Revenue beat(8)2
Avg Revenue beat(8)-32.42%
Revenue beat(12)4
Avg Revenue beat(12)-16.52%
Revenue beat(16)6
Avg Revenue beat(16)-17.87%
PT rev (1m)-1.11%
PT rev (3m)-0.22%
EPS NQ rev (1m)0%
EPS NQ rev (3m)0%
EPS NY rev (1m)-14.61%
EPS NY rev (3m)-11.06%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)-24.95%
Revenue NY rev (3m)369.43%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S N/A
P/FCF N/A
P/OCF N/A
P/B 3.21
P/tB 3.31
EV/EBITDA N/A
EPS(TTM)-4.5
EYN/A
EPS(NY)-5.88
Fwd EYN/A
FCF(TTM)-3.04
FCFYN/A
OCF(TTM)-2.98
OCFYN/A
SpS0
BVpS12.12
TBVpS11.74
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -23.46%
ROE -26.49%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-25.08%
ROA(5y)-24.01%
ROE(3y)-28.89%
ROE(5y)-28.2%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score3
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 87.18%
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 14.2
Quick Ratio 14.2
Altman-Z 14.39
F-Score3
WACC9.86%
ROIC/WACCN/A
Cap/Depr(3y)128.3%
Cap/Depr(5y)124.37%
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-23.52%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-61.73%
EPS Next Y-49.65%
EPS Next 2Y-28.29%
EPS Next 3Y-18.15%
EPS Next 5Y19.04%
Revenue 1Y (TTM)-100%
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next Year2012.42%
Revenue Next 2Y914.86%
Revenue Next 3Y697.5%
Revenue Next 5Y442.36%
EBIT growth 1Y-41.53%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year-46.65%
EBIT Next 3Y-20.64%
EBIT Next 5Y11.15%
FCF growth 1Y-58.45%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-59.01%
OCF growth 3YN/A
OCF growth 5YN/A